🏠 Home How to use e-mentor 🎁 Earn Gifts by Studying
📚 Study Hub
🤖 AI Study PlannerPAID 🔁 Recap Cards ⚔️ 1v1 Study Duels NEW 📋 Test Series 💎 Test Series PackagesTIERS 🎁 Invite FriendsFREE PLANNER 📖 Track Chapters
⚡ Focus & Tools
🎧 Virtual Focus Room LIVE ⏱ Pomodoro Timer 🏆 Leaderboard 🎁 Earn Gifts by Studying
🌐 Community & Info
✍️ Blog ❓ Frequently Asked Questions ℹ️ Read Me First
Login Join Free
📢 UPDATES
📅 25th All India Debate Competition 2026  |  🏆 Leaderboard resets weekly — Keep your streak alive!  |  💡 Join Discussion Board for exam doubt clearing  |  📅 25th All India Debate Competition 2026  |  🏆 Leaderboard resets weekly — Keep your streak alive!  |  💡 Join Discussion Board for exam doubt clearing  | 

Ch 5: ACCOUNTING FOR DEBENTURES — V2: Applied Practical Scenarios & Financial Computations

CS Executive 📚 Corporate Accounting & Financial Management 📖 Ch.5 — ACCOUNTING FOR DEBENTURES 📘 V2: Study Material & Test Yourself ⚡ Free Mode (Answers Locked)
⏱ Duration: 90 Mins 🎯 Total Marks: 50 Passed at: 20 Marks Max Attempts: 10
⚖️ Statutory Applicability: Applicable for ICSI CS Executive Examinations (December 2026 Attempt - Syllabus 2022)

Exhaustive ICSI CS Executive Test Series with 4-Tier Rubrics, Statutory Analysis, and Real-world Corporate Problem Scenarios.

Login to Enroll & Start Join Free

📑 Exam Questions

5 Questions • Total 50 Marks

Question 1: PRACTICAL NUMERICAL: Issue of debentures with conditions of redemption (issued at par redeemable at premium, issued at discount redeemable at premium).

10 Marks
📌 Companies (Share Capital and Debentures) Rules read with recent MCA notifications regarding DRR requirements for listed and unlisted companies.
M/s Vanguard Industries Limited decided to raise long-term capital by issuing two distinct series of 9% Debentures on 1st April 2023. The particulars of the two series are structured in the table below. You are required to pass necessary journal entries in the books of the company for the financial year 2023-24, prepare the relevant extracts of the Balance Sheet as at 31st March 2024, and provide detailed working notes. ### Financial Problem Data Table | Series Identifier | Number & Denomination of Debentures | Terms of Issue | Terms of Redemption | Date of Issue | Date of Redemption | |-------------------|--------------------------------------|----------------|---------------------|---------------|--------------------| | Series A | 10,000 Debentures of ₹ 100 each | Issued at Par | Redeemable at 10% Premium | 1st April 2023 | 31st March 2028 | | Series B | 15,000 Debentures of ₹ 100 each | Issued at 5% Discount | Redeemable at 8% Premium | 1st April 2023 | 31st March 2029 |
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)

Question 2: PRACTICAL NUMERICAL: Writing off discount/loss on issue of debentures over debenture tenure.

10 Marks
📌 Companies Act, 2013 Schedule III disclosures and Ind AS 109 effective interest rate amortisation principles.
M/s Kalinga Pharma Limited issued 10,000, 9% Debentures of Rs. 100 each on 1st April, 2021, redeemable at a premium of 5% at the end of 5 years. The issue price was fixed at a discount of 6%. The company follows the financial year ending 31st March. As per the terms of issue, the underwriting commission of 2% was also payable. The company decided to write off the discount and loss on issue of debentures as well as underwriting commission over the tenure of the debentures using the straight-line method as well as the effective interest / outstanding debenture method. The following tables summarize the financial data and redemption schedule. Table 1: Debenture Issue Particulars | Particulars | Details | | :--- | :--- | | Face Value per Debenture | Rs. 100 | | Number of Debentures Issued | 10,000 | | Total Face Value | Rs. 10,00,000 | | Issue Price per Debenture | Rs. 94 (At 6% Discount) | | Redemption Price per Debenture | Rs. 105 (At 5% Premium) | | Tenure of Debentures | 5 Years | | Date of Issue | 1st April, 2021 | | Underwriting Commission Rate | 2% of Face Value | Table 2: Outstanding Debentures Balance (for Alternative Method) | Financial Year | Opening Balance of Debentures (Rs.) | Proportionate Basis | | :--- | :--- | :--- | | 2021-22 | 10,00,000 | 5 | | 2022-23 | 10,00,000 | 4 | | 2023-24 | 10,00,000 | 3 | | 2024-25 | 10,00,000 | 2 | | 2025-26 | 10,00,000 | 1 | | Total | 50,00,000 | 15 | You are required to compute the total discount and loss on issue of debentures, pass necessary journal entries for the first two years (2021-22 and 2022-23) under both the Straight-Line Method (SLM) and the Outstanding Debentures Method (ODW), and prepare the Discount/Loss on Issue of Debentures Account for both methods.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)

Question 3: PRACTICAL NUMERICAL: Creation of Debenture Redemption Reserve (DRR) and Debenture Redemption Investment (DRI), redemption of debentures in open market.

10 Marks
📌 Companies (Share Capital and Debentures) Rules, 2014 along with subsequent amendments exempting DRR for listed companies, AIFIs and Banking companies, while maintaining 10% DRR for unlisted non-banking companies and 15% DRI requirement.
M/s Kalinga Pharma Limited, an unlisted non-banking financial company registered under the Companies Act, 2013, has an authorized share capital of ₹50,00,000 divided into 5,00,000 Equity Shares of ₹10 each. The company had issued 20,000, 9% Non-Convertible Debentures (NCDs) of ₹100 each on 1st April 2021, redeemable at a premium of 5% on 31st March 2024. As per the statutory mandate and rules framed thereunder, the company is required to maintain a Debenture Redemption Reserve (DRR) and invest in specified securities (DRI). On 30th April 2023, the company purchased 4,000 of its own 9% Debentures from the open market at ₹96 per debenture (ex-interest), and immediately cancelled them. On 31st March 2024, the remaining debentures were due for redemption. The balance in the General Reserve as on 31st March 2023 was ₹8,00,000 and the Capital Reserve stood at ₹2,00,000. Interest on debentures is payable half-yearly on 30th September and 31st March every year. You are required to pass necessary Journal Entries (with detailed narrations) in the books of M/s Kalinga Pharma Limited for the financial year 2023-24 relating to the creation/adjustment of DRR, purchase and cancellation of debentures from the open market, and final redemption of the remaining debentures, along with exhaustive Working Notes.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)

Question 4: Comprehensive review of key exam provisions of ACCOUNTING FOR DEBENTURES (Part 4)

10 Marks
📌 Compliance with Section 71(4) of the Companies Act, 2013 and Rule 18(7) of the Companies (Share Capital and Debentures) Rules, 2014 regarding 10% DRR and 15% specified investments.
AstraZeneca Pharma India Limited issues 10,000 8% Redeemable Debentures of Rs. 1,000 each on April 1, 2021, redeemable on March 31, 2025, at a premium of 5%. The issue terms state that these debentures are to be redeemed out of profits. The company's Balance Sheet as at March 31, 2024, reflects the following extracts: Table 1: Equity and Liabilities Extract as at March 31, 2024 | Particulars | Note No. | Amount (Rs.) | |---|---|---| | I. Equity and Liabilities | | | | 1. Shareholder's Funds | | | | a) Share Capital (Equity Shares of Rs. 10 each fully paid) | 1 | 5,00,00,000 | | b) Reserves and Surplus | 2 | | | - Capital Redemption Reserve | | 1,00,00,000 | | - Securities Premium Account | | 50,00,000 | | - General Reserve | | 3,50,00,000 | | - Surplus i.e., Balance in Statement of Profit and Loss | | 2,00,00,000 | | 2. Non-Current Liabilities | | | | a) Long-term Borrowings (8% Redeemable Debentures) | 3 | 1,00,00,000 | Table 2: Assets Extract as at March 31, 2024 | Particulars | Note No. | Amount (Rs.) | |---|---|---| | II. Assets | | | | 1. Non-Current Assets | | | | - Fixed Assets / Investments (including 15% DRR Investment) | 4 | As per statutory requirement | Additional Information: 1. In compliance with Rule 18(7) of the Companies (Share Capital and Debentures) Rules, 2014, the company maintains the required Debenture Redemption Reserve (DRR) and invests the statutory percentage of debentures maturing during the next financial year in specified securities. 2. On March 31, 2025, the debentures are due for redemption. The company realizes its investments at par and utilizes the bank balance along with available reserves to effect the redemption including premium. You are required to pass necessary Journal Entries (with detailed narrations) in the books of AstraZeneca Pharma India Limited for the financial year 2024-25 relating to DRR creation/adjustment, DRR investment encashment, debenture redemption liability settlement, and transfer of unutilized DRR to General Reserve, along with supporting working notes.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)

Question 5: Comprehensive review of key exam provisions of ACCOUNTING FOR DEBENTURES (Part 5)

10 Marks
📌 Companies (Share Capital and Debentures) Amendment Rules regarding DRR and DRI percentages for unlisted companies.
Sahyadri Chemicals Limited issues 10,000 9% Debentures of face value Rs. 1,000 each at a discount of 10% redeemable at a premium of 5% at the end of 5 years. Under the terms of issue, the debentures are to be redeemed by draw of lots as follows: End of Year 3: 3,000 Debentures; End of Year 4: 3,000 Debentures; End of Year 5: 4,000 Debentures. The company maintains the statutory Debenture Redemption Reserve (DRR) and makes required Debenture Redemption Investments (DRI) as per Rule 18(7) of the Companies (Share Capital and Debentures) Rules, 2014. Prepare necessary Journal Entries for the first year of issue and redemption, compute the exact DRR and DRI amounts for each year, and show the extract of the Balance Sheet at the end of Year 1.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)
Advertisement

Quick Pomodoro Timer

Select a focus duration to launch your session:

25m Standard 50m Deep Focus 15m Quick Sprint
🎧 Join Virtual Focus Room (with 40Hz Audio) →
🔔
Daily Study Reminders
Get notified 15m before your target study sessions.